### **Characteristics of Cases of Priority Fungal Diseases**

### Request for OMB approval of a Revision of a Currently Approved Collection

OMB Control Number 0920-1385

#### October 15, 2024

#### Supporting Statement B

**Contact:**

Rudith Vice

National Center for Emerging and Zoonotic Infectious Diseases

Centers for Disease Control and Prevention

1600 Clifton Road, NE

Atlanta, Georgia 30333

Phone: (404) 718-7292

Email: nhr9@cdc.gov

#### Table of Contents

[1. Respondent Universe and Sampling Methods 2](#_Toc473882440)

[2. Procedures for the Collection of Information 2](#_Toc473882441)

[3. Methods to maximize Response Rates and Deal with No Response 2](#_Toc473882442)

[4. Tests of Procedures or Methods to be Undertaken 2](#_Toc473882443)

[5. Individuals Consulted on Statistical Aspects and Individuals Collecting and/or Analyzing Data 2](#_Toc473882444)

The collection does not involve statistical methods. Making statistical generalizations beyond the particular respondents is not the purpose of the collection.

# Respondent Universe and Sampling Methods

Case report forms (CRF) will be voluntarily completed by state, local or tribal health departments, federal agencies, and members of the private sector (e.g., academic institutions) when cases of the priority fungal diseases are detected. In some cases, states may collect data for a subset of cases, in which case the Mycotic Diseases Branch will work with state partners to ensure a representative sample.

# Procedures for the Collection of Information

We plan to use standardized CRFs to collect public health surveillance data for cases of these diseases regarding demographics (e.g., age, sex, race/ethnicity, location of residence), underlying medical conditions, diagnosis (e.g., clinical presentation, laboratory testing), treatments, and outcomes (e.g., hospitalization, vital status). The corresponding CRF would be filled out voluntarily by state, local or tribal health departments, federal agencies, and members of the private sector (e.g., academic institutions) and contains a section for medical chart review and an optional supplemental interview (including data on potential occupational or environmental exposures) of the patient or their representative.

# Methods to maximize Response Rates and Deal with No Response

Not applicable

# Tests of Procedures or Methods to be undertaken

No pretests are planned.

# Individuals Consulted on Statistical Aspects and Individuals Collecting and/or Analyzing Data

None.